Subjects with preexisting cardiovascular symptoms who were receiving subutramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 10162 overweight or obese subjects with preexisting cardiovascular disease and/or type 22 diabetes. The subjects were randomly assigned to subutramine (5083 subjects) or a placebo (5079 subjects) in a double‑blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after cardiac arrest, or cardiovascular death. The primary outcome was observed in 572 subjects in the subutramine group and 506 subjects in the placebo group. Do the data give good reason to think that there is a difference between the proportions of treatment and placebo subjects who experienced the primary outcome? (Note that sibutramine has not been available in the United States since the end of 2010 due to its manufacturer's concerns over increased risk of heart attack or stroke, although at the present time, it can still be purchased in other countries.) State hypotheses and then find the test statistic. Give your answer to two decimal places. ?= Use either software or the bottom row of Table C for the ?-value.. Give your answer to four decimal places. ?-value:

MATLAB: An Introduction with Applications

6th Edition

ISBN:9781119256830

Author:Amos Gilat

Publisher:Amos Gilat

Chapter1: Starting With Matlab

Section: Chapter Questions

Problem 1P

See similar textbooks

Related questions

Question

Subjects with preexisting cardiovascular symptoms who were receiving subutramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 10162 overweight or obese subjects with preexisting cardiovascular disease and/or type 22 diabetes. The subjects were randomly assigned to subutramine (5083 subjects) or a placebo (5079 subjects) in a double‑blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after cardiac arrest, or cardiovascular death. The primary outcome was observed in 572 subjects in the subutramine group and 506 subjects in the placebo group.

Do the data give good reason to think that there is a difference between the proportions of treatment and placebo subjects who experienced the primary outcome?

(Note that sibutramine has not been available in the United States since the end of 2010 due to its manufacturer's concerns over increased risk of heart attack or stroke, although at the present time, it can still be purchased in other countries.)

State hypotheses and then find the test statistic. Give your answer to two decimal places.